LY6K Antibody, FITC conjugated

1. breast cancer risk and metastasis were significantly associated with not only LY6K expression, but also methylation of CGI shore which induced by SNP242 mutation. PMID: 27494879
2. miR-192-5p, induced by LY6K, downregulates ERalpha directly and induced tamoxifen resistance in ERalpha-positive breast cancer cells; re-expression of ERalpha in ERalpha-negative breast cancer cells increased miR-500a-3p expression and directly inhibits LY6K expression PMID: 27304060
3. LY6K overexpression is associated with Breast Cancer Progression, Immune Escape, and Drug Resistance. PMID: 27197181
4. Data show that TTK protein kinase, lymphocyte antigen 6 complex locus K and insulin-like growth factor (IGF)-II mRNA binding protein 3 are tumor-associated antigens recognized by cytotoxic T lymphocytes and HLA-A24-restricted epitope peptides. PMID: 17784873
5. AP-1 activation has an important role in promoting LY6K gene expression that regulates cell mobility of breast cancer cells PMID: 22988241
6. it appears that LY6K is constitutively overexpressed either by copy number changes, or by yet unknown mechanisms in gingivobuccal squamous cell carcinoma PMID: 22072328
7. Useful as a tumor biomarker and probably as a target for the development of new molecular therapies for cancer treatment. PMID: 18089789

Show More

Hide All

HGNC: 24225

OMIM: 615093

KEGG: hsa:54742

STRING: 9606.ENSP00000453042

UniGene: Hs.69517